Compounds > carbostyril
Page last updated: 2024-08-17

carbostyril and Parkinson Disease, Secondary

carbostyril has been researched along with Parkinson Disease, Secondary in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (44.44)18.2507
2000's0 (0.00)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belletti, A; Cilia, R; Marotta, G; Pezzoli, G; Siri, C1
Danysz, W; Dekundy, A; Gravius, A; Hechenberger, M; Mela, F; Nagel, J; Parsons, CG; Pietraszek, M; Tober, C; van der Elst, M1
Albayrak, Y; Caykoylu, A; Ekinci, O; Ugurlu, GK1
Ishitobi, M; Kosaka, H; Murata, T; Oonuma, M; Takahashi, T; Wada, Y1
Miranda C, M; Retamal C, P1
Asin, KE; Bianchi, B; Britton, DR; Didomenico, S; Hodges, L; Hong, Y; Jenner, P; Lin, CW; Mahan, L; Michaelides, M; Mikusa, J; Miller, T; Nikkel, A; Shiosaki, K; Smith, L; Stashko, M; Williams, M; Witte, D1
Asin, KE; Bayburt, EK; Britton, DR; DiDomenico, S; Hong, Y; Lin, CW; Michaelides, MR; Shiosaki, K1
Bédard, PJ; Britton, DR; Grondin, R; Shiosaki, K1
Coper, H; Konieczny, J; Ossowska, K; Schulze, G; Wolfarth, S1

Other Studies

9 other study(ies) available for carbostyril and Parkinson Disease, Secondary

ArticleYear
Reversible dopamine transporter reduction in drug-induced Parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 2014, Volume: 29, Issue:4

    Topics: Aged; Aripiprazole; Bipolar Disorder; Brain; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Lithium Carbonate; Parkinson Disease, Secondary; Piperazines; Quinolones; Radionuclide Imaging

2014
Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Adrenergic Agents; Allosteric Regulation; Analysis of Variance; Animals; Brain; Calcium; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Fear; In Vitro Techniques; Levodopa; Male; Maze Learning; Microdialysis; Monoamine Oxidase Inhibitors; Motor Activity; Oxidopamine; Pain Measurement; Parkinson Disease, Secondary; Picolinic Acids; Psychomotor Performance; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rotarod Performance Test; Tandem Mass Spectrometry; Time Factors

2011
Aripiprazole-associated bruxism, akathisia, and parkinsonism in a bipolar patient.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:1

    Topics: Akathisia, Drug-Induced; Aripiprazole; Bipolar Disorder; Bruxism; Female; Humans; Parkinson Disease, Secondary; Piperazines; Quinolones; Young Adult

2011
Aripiprazole monotherapy in the treatment of vascular parkinsonism.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:6

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Parkinson Disease, Secondary; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome

2011
[Potentiation of Aripiprazole extrapiramidal adverse effects with the concomitant use of serotonin selective reuptake inhibitors].
    Revista medica de Chile, 2011, Volume: 139, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors

2011
ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 1996, Volume: 276, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; CHO Cells; Corpus Striatum; Cricetinae; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Fishes; Humans; Kinetics; Male; Mice; Parkinson Disease, Secondary; Prodrugs; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Tetrahydronaphthalenes; Thiophenes

1996
Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.
    Journal of medicinal chemistry, 1997, May-23, Volume: 40, Issue:11

    Topics: Adenylyl Cyclases; Animals; Benzazepines; Binding, Competitive; Cell Membrane; Corpus Striatum; Dopamine Agonists; Dopamine Antagonists; Fishes; Mice; Molecular Structure; Oxidopamine; Parkinson Disease, Secondary; Quinolones; Receptors, Dopamine; Retina; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Tritium; Yohimbine

1997
Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Neurology, 1997, Volume: 49, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease, Secondary; Quinolones; Quinpirole; Receptors, Dopamine D1; Thiophenes

1997
L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats.
    Psychopharmacology, 1999, Volume: 143, Issue:3

    Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Dopamine Antagonists; Electromyography; Excitatory Amino Acid Antagonists; Female; Haloperidol; Male; Muscle Rigidity; Muscle Tonus; Parkinson Disease, Secondary; Quinolones; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate

1999